David R. Jones

发表

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

J. Gorski, B. Haehner‐Daniels, S. Hall, 1998, Clinical pharmacology and therapeutics.

Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation

Dawn L. Moore, David R. Jones, M. Scheetz, 2016, Pharmacotherapy.

Studies on the rust fungi Uromyces dianthi (Pers.) Niessl. and Puccinia arenariae (Schum.) Wint.

David R. Jones, 1972 .

Identifying the cause of Oyster Oedema Disease (OOD) in pearl oysters (Pinctada maxima), and developing diagnostic tests for OOD

D. Raftos, David R. Jones, M. Snow, 2017 .

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N‐demethylation

D. Jones, J. Gorski, S. Hall, 1996, Clinical pharmacology and therapeutics.

The interaction of diltiazem with lovastatin and pravastatin

S. Hall, David R. Jones, D. Brater, 1998, Clinical pharmacology and therapeutics.

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

David A. Flockhart, Zeruesenay Desta, Stephen D. Hall, 2003, Journal of Pharmacology and Experimental Therapeutics.

Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.

B. Ring, S. Wrighton, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

D. Jones, J. Gorski, S. Hall, 1999, The Journal of pharmacology and experimental therapeutics.

Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

C. Ernest, S. Hall, David R. Jones, 2005, Journal of Pharmacology and Experimental Therapeutics.

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

S D Hall, S. Wrighton, D. Jones, 1994, Biochemical pharmacology.

An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

S D Hall, D. Jones, S. Hall, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

S. Wrighton, D. Jones, J. Gorski, 1999, Xenobiotica; the fate of foreign compounds in biological systems.